Grenye O'Malley1, Ally Wang2, Selassie Ogyaadu2, Carol J Levy3. 1. Icahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA. omallg01@mssm.edu. 2. Icahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA. 3. Icahn School of Medicine At Mount Sinai, Division of Endocrinology, Diabetes and Bone Disease, New York, NY, USA. carol.levy@mssm.edu.
Abstract
PURPOSE OF REVIEW: Diabetes during pregnancy increases the risk of maternal and fetal complications. This article reviews the types of CGM currently available, the glucose metrics which correlate with pregnancy outcomes, endocrine organization recommendations, clinical considerations for CGM implementation, and anticipated directions for future research. RECENT FINDINGS: CGM use during pregnancy is increasing, and recommendations for use have been incorporated into many organizations' consensus guidelines. Increased time spent within a target range of 63-140 mg/dL and lower mean glucose are associated with lower risk of neonatal complications including large for gestational age infants. Use of CGM during pregnancy can detect postprandial and nocturnal hyperglycemia missed by self-monitoring of blood glucose (SMBG) which can be used for prognosis and to guide pharmacologic interventions. The use of continuous glucose monitoring (CGM) during pregnancies complicated by type 1, type 2, and gestational diabetes has been shown to improve outcomes.
PURPOSE OF REVIEW: Diabetes during pregnancy increases the risk of maternal and fetal complications. This article reviews the types of CGM currently available, the glucose metrics which correlate with pregnancy outcomes, endocrine organization recommendations, clinical considerations for CGM implementation, and anticipated directions for future research. RECENT FINDINGS: CGM use during pregnancy is increasing, and recommendations for use have been incorporated into many organizations' consensus guidelines. Increased time spent within a target range of 63-140 mg/dL and lower mean glucose are associated with lower risk of neonatal complications including large for gestational age infants. Use of CGM during pregnancy can detect postprandial and nocturnal hyperglycemia missed by self-monitoring of blood glucose (SMBG) which can be used for prognosis and to guide pharmacologic interventions. The use of continuous glucose monitoring (CGM) during pregnancies complicated by type 1, type 2, and gestational diabetes has been shown to improve outcomes.
Authors: Mengying Li; Stefanie N Hinkle; Katherine L Grantz; Sungduk Kim; Jagteshwar Grewal; William A Grobman; Daniel W Skupski; Roger B Newman; Edward K Chien; Anthony Sciscione; Noelia Zork; Deborah A Wing; Michael Nageotte; Fasil Tekola-Ayele; Germaine M Buck Louis; Paul S Albert; Cuilin Zhang Journal: Lancet Diabetes Endocrinol Date: 2020-03-02 Impact factor: 32.069
Authors: Mary C M Macintosh; Kate M Fleming; Jaron A Bailey; Pat Doyle; Jo Modder; Dominique Acolet; Shona Golightly; Alison Miller Journal: BMJ Date: 2006-06-16
Authors: Dorte M Jensen; Peter Damm; Lars Moelsted-Pedersen; Per Ovesen; Jes G Westergaard; Margrethe Moeller; Henning Beck-Nielsen Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Helen R Murphy; Carla Howgate; Jackie O'Keefe; Jenny Myers; Margery Morgan; Matthew A Coleman; Matthew Jolly; Jonathan Valabhji; Eleanor M Scott; Peter Knighton; Bob Young; Nick Lewis-Barned Journal: Lancet Diabetes Endocrinol Date: 2021-01-28 Impact factor: 32.069
Authors: Michael J A Maresh; Valerie A Holmes; Christopher C Patterson; Ian S Young; Donald W M Pearson; James D Walker; David R McCance Journal: Diabetes Care Date: 2014-11-03 Impact factor: 19.112
Authors: Helen R Murphy; Ruth Bell; Cher Cartwright; Paula Curnow; Michael Maresh; Margery Morgan; Catherine Sylvester; Bob Young; Nick Lewis-Barned Journal: Diabetologia Date: 2017-06-08 Impact factor: 10.122